Now that the Abbott Freestyle Libre has received FDA clearance, Abbott and Dexcom will be forced into tight competition in the US market. On Dexcom’s third quarter call, CEO Kevin Sayer spent some ...
Dexcom reported second-quarter results on Friday, July 26. Management lowered its forward revenue outlook because of unexpected challenges with its new glucose monitoring device. Dexcom's main ...
DexCom has built itself an impressive market position against large competitors in the diabetes space. Future growth should remain relatively easy as reimbursed populations continue to grow, and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results